Xiaolin Wei MD, MPH, PhD
- Email Address(es)
- Office Phone
- 416 978 2020
- Office Address
- 582-155 College Street, Toronto, ON M5T 3M7, Canada
- Global Implementation Science Lab
- Clinical Public Health Division
Institute of Health Policy, Management & Evaluation
- SGS Status
- Full Member
- Appointment Status
- Currently Accepting Doctoral Students?
- Implementation Science
- Antimicrobial resistance
- Diabetes and hypertension
- Primary care
- Global health
- One health
Xiaolin is a medical doctor, public health specialist, professor and the Dalla Lana Chair in Global Health Policy in the Dalla Lana School of Public Health (DLSPH), University of Toronto. He was elected as a Fellow of Canadian Academy of Health Sciences in 2022. Xiaolin is the faculty co-lead for implementation science. He serves as a board member and has served as the Secretary General and Vice President of the International Union of Lung Disease. He also holds adjunct/visiting professorship with the Johns Hopkins University, USA, the University of St. Andrews, Scotland and Peking University, China. He regularly provides consultancy to the World Health Organization regarding tuberculosis, antimicrobial resistance and implementation science/ clinical trials design.
Education & training history
- 2012- Fellow, Faculty of Public Health, UK
- 2004 – PhD, University of Toronto, Canada
- 2001 – MSc in Health Admin, Peking University, China
- 1998 – MD, Jining Medical School, China
- CHL5632H: Application of Implementation Science in Global Health
- CHL5631H: Integrating Public Health and Clinical Care: The case of TB
- HAD5778H: Comparative Health Systems and Policy (with Dr. Sara Allin)
- CHL5005H (PhD stream): Introduction to Public Health Research: 2017-2019
- Full SGS member, supervising PhD student in Health Service Research in IHPME
Ongoing Research Projects (as PI)
2021-2023. Developing a tool kit to build vaccine confidence and ensure equitable COVID-19 vaccination implementation strategies in low-and-middle income countries: a multi-stakeholder implementation science and co-development study, by Canadian Institutes of Health Research
2022-2023. Implementing a telemedicine and remote-mentoring platform to provide integrated noncommunicable disease and COVID- 19 care in primary care facilities in rural Pakistan, by Canadian Institutes of Health Research
2020-2023 Developing integrated guidelines for health care workers in hospital and primary healthcare facilities in response to Covid-19 pandemic in Low- and Middle-Income Countries (LMICs), 2020-2022, by Canadian Institutes of Health Research
2019-2024. Antibiotic stewardship program in primary care facilities to reduce inappropriate antibiotic prescribing for acute respiratory tract infections: a clustered randomised controlled trial and follow-up study in rural China, 2019-2024, by China Primary Care Foundation
My academic contribution has been focused on disease control and primary care in four areas: 1) primary care policy; 2) antimicrobial resistance (AMR); 3) tuberculosis (TB); and 4) hypertension and diabetes. This are all high profile global and local public health challenges. My research program has been strongly linked to creative professional activities in employing implementation science frameworks to change practice and health policies in low and middle-income countries (LMICs). Through my research, I have established extensive partnerships with health authorities, NGOs and academics in several LMICs (including China, the Philippines, Cambodia, Indonesia, Pakistan, Nepal, Bangladesh, Sri Lanka, Ghana, Uganda and Swaziland). I have led randomized trials to change clinical practice and make impacts at the policy level in areas of antimicrobial resistance, tuberculosis control and diabetes/ hypertension care. I currently lead a pragmatic trial to investigate the effect of employing telemedicine to improve care for hypertension and COVID-19 in rural Pakistan. I have published over 140 peer reviewed research papers, and held over $10m research funding as the principal investigator from MRC, DFID, CIHR, StopTB Partnership and HK RGC.
Recent selected publications :
Wu S, Li Y, Mishra S, Bodner K, Baral S, Kwong JC, Wei X*. Effect of the incremental protection of previous infection against Omicron infection among individuals with a hybrid of infection- and vaccine-induced immunity: a population-based cohort study in Canada. Int J Infect Dis. 2023;127:69-73.
Wu S, Tannous E, Haldane V, Ellen ME, Wei X*. Barriers and facilitators of implementing interventions to improve appropriate antibiotic use in low- and middle-income countries: a systematic review based on the Consolidated Framework for Implementation Research. Implement Sci. 2022;17(1):30.
Dodd W, Brubacher LJ, Kipp A, Wyngaarden S, Haldane V, Ferrolino H, Wilson K, Servano D Jr, Lau L, Wei X*. Navigating fear and care: The lived experiences of community-based health actors in the Philippines during the COVID-19 pandemic. Soc Sci Med. 2022;308:115222.
Haldane V, Li BP, Ge S, Huang JZ, Huang H, Sadutshang L, Wei X*. Exploring the translation process for multilingual implementation research studies: a collaborative autoethnography. BMJ Glob Health. 2022;7(5).
Wei, X., Zhang Z, Chong M, Hicks J, Gong W, Zou G, Zhong J, Walley, J.D., Upshur R, Yu, M. 2021, Effect of a package of risk-based pharmaceutical and lifestyle interventions on patients with hypertension and/or diabetes in rural China: a pragmatic cluster randomised controlled trial, PLoS Med 18(7): e1003694. https://doi.org/10.1371/journal. pmed.1003694
Zou G, Zhang W, King R, Zhang Z, Walley J, Gong W, Yu M, Wei X*. Process Evaluation of a Clustered Randomized Control Trial of a Comprehensive Intervention to Reduce the Risk of Cardiovascular Events in Primary Health Care in Rural China. Int J Environ Res Public Health. 2020;17(11).
Zhuo C, Wei X*, Zhang Z, Hicks JP, Zheng J, Chen Z, Haldane V, Walley J, Guan Y, Xu H, Zhong Nanshan. An antibiotic stewardship programme to reduce inappropriate antibiotic prescribing for acute respiratory infections in rural Chinese primary care facilities: study protocol for a clustered randomised controlled trial. Trials. 2020;21(1):394.
Haldane V, Ratnapalan S, Perera N, Zhang Z, Ge S, Choi M, Lau LL, Samaraweera S, Dodd W, Walley J, Wei X*.: Codevelopment of COVID-19 infection prevention and control guidelines in lower-middle-income countries: the ‘SPRINT’ principles. BMJ Glob Health 2021, 6(8).
Lau LL, Hung N, Go DJ, Ferma J, Choi M, Dodd W, Wei X. Knowledge, attitudes and practices of COVID-19 among income-poor households in the Philippines: A cross-sectional study. J Glob Health. 2020;10(1):011007.
Haldane V, Zhang Z, Abbas RF, Dodd W, Lau LL, Kidd MR, Rouleau, K., Zou, G., Chao, Z., Upshur, R.,Walley, J, Wei X*. National primary care responses to COVID-19: a rapid review of the literature. BMJ Open. 2020;10(12):e041622
Wei X*, Deng S, Haldane V, Blacklock C, Zhang W, Walley J, King R, et al. Understanding complex interventions to reduce antibiotic prescribing in rural China: a process evaluation of a randomised controlled trial. Journal of health services research & policy. 2020;25(2):94-103.
Wei X, Zhang Z, Hicks JP, Walley JD, King R, Newell JN, Yin, J., Zeng, J., Guo, Y., Lin, M., Upshur, R. E. G., Sun, Q. “Long-term outcomes of an educational intervention to reduce antibiotic prescribing for childhood upper respiratory tract infections in rural China: Follow-up of a cluster-randomised controlled trial”. PLoS Med. 2019;16(2):e1002733.
Zhang Z, Dawkins B, Hicks JP, Walley JD, Hulme C, Elsey H., Deng SM., Lin M., Zeng J., Wei, X*. “Cost-effectiveness analysis of a multi-dimensional intervention to reduce inappropriate antibiotic prescribing for children with upper respiratory tract infections in China”. Tropical medicine & international health : TM & IH. 2018;23(10):1092-100.
Wei X, Zhang Z, Walley JD, Hicks JP, Zeng J, Deng S, Zhou Y, Yin J, Newell JN, Sun Q, Zou G, Guo Y, Upshur R, Lin M. “Effect of a training and educational intervention for physicians and caregivers on antibiotic prescribing for upper respiratory tract infections in children at primary care facilities in rural China: a cluster-randomised controlled trial”. Lancet Glob Health. 2017;5(12):e1258-e67.
Wei X, Yin J, Walley JD, Zhang Z, Hicks JP, Zhou Y, Sun Q, Zeng J., Lin M. “Impact of China’s essential medicines scheme and zero-mark-up policy on antibiotic prescriptions in county hospitals: a mixed methods study”. Tropical medicine & international health : TM & IH. 2017;22(9):1166-74.
Walker IF, Shi OM, Hicks JP, Elsey H, Wei X., Menzies D., Falzon D, Migliori GB, Perez-Guzman C, Vargas MH, Garcia-Garcia L, Osornio JS, Ponce-De-Leon A, Van der Walt M, Newell JN. “Analysis of loss to follow up in 4,099 multidrug-resistant pulmonary tuberculosis patients”. European Respiratory Journal. 2019; 54(1)
Wei X, Hicks JP, Pande P, Zhang Z, Haldane V, Liu XQ, et al. “Protocol for a randomised controlled trial to evaluate the effectiveness of improving tuberculosis patients’ treatment adherence via electronic monitors and an app versus usual care in Tibet”. Trials. 2019;20(1):273
Li B, Zhang XL, Guo J, Wang J, Pianduo B, Wei XL, Ying TT, Hu J. “The Prevalence of pulmonary tuberculosis in Tibet Autonomous Region, China in 2014”. The international journal of tuberculosis and lung disease. 2019;23(6):735-740
Ge E, Li D, Luo M, Tsui KWS, Waye MMY, Shen X, Wei X*. “Transmission of multidrug-resistant tuberculosis in Shanghai: roles of residential status”. The international journal of tuberculosis and lung disease. 2018;22(12):1462-8.
Chen B, Gu H, Wang X, Wang F, Peng Y, Ge E, Wei X.* “Prevalence and determinants of latent tuberculosis infection among frontline tuberculosis healthcare workers in southeastern China: A multilevel analysis by individuals and health facilities”. Int J Infect Dis. 2018;79:26-33.
Yin, J.#, Yuan, J., Hu, Y., & Wei, X*. (2016). “Association between Directly Observed Therapy and Treatment Outcomes in Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis”. PloS One. 11(3), e0150511. Doi:10.1371/journal.pone.0150511
Wei X, Yin J, Zhang ZT, Walley J, Harwell J, Li H, Li R, Wang L, Sun Q, and Zhang XL, (2015), “Treatment Interruptions and Provision of Directly Observed Treatment of Multidrug Resistant Tuberculosis Patients in China”. Journal of International Union against TB and Lung Disease. 19(4):413–419
Wei, X., Walley, J.D., Zhang, Z., Zou, G., Gong, W., Deng, S., Harries, A.D., Hicks, J.P., Chong, M.K.C., Newell, J.N., Zhong, J., Yu, M. 2017. “Implementation of a comprehensive intervention for patients at high risk of cardiovascular disease in rural China: A pragmatic cluster randomized controlled trial”. PLoS One. 12, e0183169.
Wei X*, Li H, Yang N, Wong YSS, Chong MCK, Shi, L, Wong MCS, Xu J, Zhang D, Tang J, Li DKT, Meng Q, Griffiths S, (2015). “Changes of primary care quality in two megacities of China between 2011 and 2013: a multivariate difference-in-difference analysis”, Bulletin of the World Health Organization 93:407-16
Full publication list available at: https://www.researchgate.net/profile/Xiaolin_Wei2